Literature DB >> 30384958

Modifications of Callender's Classification of Uveal Melanoma at the Armed Forces Institute of Pathology.

Ian W McLean1, Walter D Foster1, Lorenz E Zimmerman1, John W Gamel2.   

Abstract

One hundred well-documented cases of uveal melanoma accessioned at the Armed Forces Institute of Pathology before 1970 were reviewed and reclassified to identify changes made in the Callender classification. We compared the new classification with the original classification to determine the effect of the changes on the prediction of outcome for the patient after enucleation. Staff pathologists had originally classified 52 of the 100 cases as spindle-cell type melanoma. Only 31 of the 100 cases were reclassified as spindle-cell types (two spindle-cell nevi and 29 spindle-cell melanomas). Tumors classified as mixed-cell type were further subdivided into groups based on the percentage and size of the epithelioid cells. Tumors formerly classified as spindle-cell type that contained small or rare epithelioid cells were reclassified as mixed-cell type. This improved the prediction of outcome for the patient. We found that nucleolar size and pleomorphism are important variables that should be considered in the classification of uveal melanomas.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30384958     DOI: 10.1016/j.ajo.2018.08.025

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  2 in total

1.  The Macro-Autophagy-Related Protein Beclin-1 Immunohistochemical Expression Correlates With Tumor Cell Type and Clinical Behavior of Uveal Melanoma.

Authors:  Giuseppe Broggi; Antonio Ieni; Daniela Russo; Silvia Varricchio; Lidia Puzzo; Andrea Russo; Michele Reibaldi; Antonio Longo; Giovanni Tuccari; Stefania Staibano; Rosario Caltabiano
Journal:  Front Oncol       Date:  2020-11-20       Impact factor: 6.244

2.  Retrospective analysis of secondary enucleation for uveal melanoma after plaque radiotherapy.

Authors:  Heng Wang; Ruiheng Zhang; Yining Wang; Rongtian Chen; Yueming Liu; Yang Li; Wenbin Wei
Journal:  BMC Ophthalmol       Date:  2022-04-09       Impact factor: 2.209

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.